Novimmune SA has a sold a newly created vehicle comprising Gamifant (emapalumab) and related assets, two additional immune-oncology candidates and an FDA priority review voucher to Sweden’s Swedish Orphan Biovitrum AB for CHF515m ($519m). The acquisition comes less than a year after Novimmune granted Sobi an exclusive worldwide license for Gamifant. The acquisition fits in Sobi's sweet spot for rebalancing its portfolio and enhancing its immunology activities [Sidebar#SC125391].
Specifically, Sobi is gaining access to all assets relating to Gamifant, including intellectual property, patent rights, data and know-how, all...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
